8-K: Matinas BioPharma Reports Q1 2024 Financial Results and Provides Business Update

Matinas BioPharma announced its first quarter 2024 financial results, highlighting a recent $10 million financing and ongoing partnership discussions for its lead drug candidate, MAT2203.

Summary

• Matinas BioPharma reported no revenue for the first quarter of 2024, compared to $1.1 million in the same period last year, which was generated from research collaborations.
• Total costs and expenses decreased to $5.9 million in Q1 2024 from $6.7 million in Q1 2023, primarily due to lower clinical development, personnel, and administrative costs.
• The net loss for the quarter was $5.8 million, or $0.03 per share, compared to a net loss of $5.5 million, or $0.03 per share, in the first quarter of 2023.
• As of March 31, 2024, the company had $8.1 million in cash, cash equivalents, and marketable securities, down from $13.8 million at the end of 2023.
• Subsequent to the quarter, Matinas raised $10 million through a registered direct offering in April.
• The company believes its current cash position will fund operations into the second quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the recent financing and progress in partnership discussions, but tempered by the lack of revenue and ongoing losses. The technology shows promise, but the company is still in a development stage.

Positives

• The company secured $10 million in financing, extending the cash runway into the second quarter of 2025.
• Partnership discussions for MAT2203 are progressing, which could lead to significant development and commercialization opportunities.
• The LNC platform shows promise in delivering various therapeutics, including small oligonucleotides and chemotherapeutics.
• In vivo studies demonstrate reduced toxicity of IV-docetaxel when delivered using the LNC platform.
• The Compassionate/Expanded Use Access Program has enrolled 22 patients with severe fungal infections, indicating a potential unmet need.

Negatives

• The company reported no revenue for the first quarter of 2024, a decrease from $1.1 million in the same period last year.
• Cash reserves decreased from $13.8 million at the end of 2023 to $8.1 million as of March 31, 2024.
• The company experienced a net loss of $5.8 million for the quarter, slightly higher than the $5.5 million loss in the first quarter of 2023.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital.
• There are risks associated with the successful completion of clinical trials and obtaining regulatory approvals.
• The company faces competition and the potential loss of key personnel.
• Changes in the regulatory landscape could impact the company's products.
• The company's product candidates are all in a development stage and are not available for sale or use.

Future Outlook

The company believes its current cash position is sufficient to fund planned operations into the second quarter of 2025. They are also actively pursuing a partnership to advance MAT2203 into Phase 3 trials.

Management Comments

• We remain on track with active partnership discussions to advance oral MAT2203 into the ORALTO trial in invasive aspergillosis, said Jerome D. Jabbour, Chief Executive Officer of Matinas.
• These discussions aim to secure one or more development and commercial partners for this life-changing asset with a shared sense of urgency that can maximize its value in multiple geographies.
• Our confidence in oral MAT2203 continues to build as we see further evidence of favorable outcomes in extremely ill patients, some of whom have invasive fungal infections deemed even more difficult to treat than aspergillosis.
• Last months financing strengthened our balance sheet and better positioned us to advance other studies providing a strong foundation for our LNC platform programs, he added.

Industry Context

The announcement highlights Matinas BioPharma's efforts to develop novel therapies using its LNC platform, which is relevant in the context of the growing need for effective and safer treatments for fungal infections and other diseases. The focus on oral delivery is also a key trend in the pharmaceutical industry.

Comparison to Industry Standards

• Matinas BioPharma's focus on oral delivery of amphotericin B addresses a significant unmet need, as current IV formulations are associated with significant toxicity, similar to challenges faced by companies like Gilead Sciences with their IV antifungal treatments.
• The development of LNC-miriplatin for cancer treatment is comparable to efforts by companies like Merrimack Pharmaceuticals, which have explored nanoparticle delivery systems for chemotherapeutics.
• The company's compassionate use program is similar to programs offered by other biotech companies, such as Vertex Pharmaceuticals, to provide access to experimental treatments for patients with severe conditions.
• The financial results, with a decrease in revenue and a net loss, are typical for a clinical-stage biopharmaceutical company that is heavily investing in research and development, similar to companies like BioMarin Pharmaceutical.

Stakeholder Impact

• Shareholders may be concerned about the lack of revenue and ongoing losses, but encouraged by the recent financing and potential partnerships.
• Employees may be reassured by the extended cash runway and continued development of the LNC platform.
• Patients with severe fungal infections may benefit from the development of MAT2203 and the compassionate use program.
• Potential partners may be interested in the progress of MAT2203 and the LNC platform.

Next Steps

• Matinas will continue negotiations to secure a partnership for the Phase 3 ORALTO trial of MAT2203.
• The company will assess the in vivo performance of the new LNC-miriplatin formulation.
• Matinas will present data on its LNC platform at the ASGCT annual meeting.
• The company will continue to advance its LNC platform into inflammation and oncology.

Key Dates

Keywords

Matinas BioPharma, LNC platform, MAT2203, Amphotericin B, Invasive Aspergillosis, Fungal Infections, Oral Drug Delivery, Oncology, Inflammation, Clinical Trials, Partnership, Biopharmaceutical